The estimated Net Worth of Juan C. Jaen is at least $24.1 Миллион dollars as of 26 February 2024. Juan Jaen owns over 27,032 units of Arcus Biosciences Inc stock worth over $20,164,314 and over the last 13 years he sold RCUS stock worth over $1,858,549. In addition, he makes $2,126,900 as President, Co-Founder и Director at Arcus Biosciences Inc.
Juan has made over 31 trades of the Arcus Biosciences Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 27,032 units of RCUS stock worth $543,073 on 26 February 2024.
The largest trade he's ever made was buying 66,666 units of Arcus Biosciences Inc stock on 19 March 2018 worth over $999,990. On average, Juan trades about 6,670 units every 91 days since 2012. As of 26 February 2024 he still owns at least 1,188,233 units of Arcus Biosciences Inc stock.
You can see the complete history of Juan Jaen stock trades at the bottom of the page.
Dr. Juan Carlos Jaen Ph.D. serves as President, Co-Founder, Director of the Company. He also served as the President of PACT Pharma, Inc., a biopharmaceutical company, from November 2016 until December 2017. Immediately prior to the founding of our company, Dr. Jaen served briefly in April 2015 as the President of FLX Bio, Inc. Previously, Dr. Jaen co-founded (with Dr. Rosen) and served as the President and Head of Research and Development at Flexus Biosciences, Inc. from October 2013 to April 2015, when it was acquired by Bristol-Myers Squibb. Prior to that, Dr. Jaen served as Senior Vice President of Drug Discovery and as the Chief Scientific Officer of ChemoCentryx, Inc., a biopharmaceutical company, from 2007 to September 2013. From 2004 to 2006, Dr. Jaen was Vice President of Chemistry at Amgen Inc. and from 1996 to 2004, Dr. Jaen held positions as Director of Medicinal Chemistry and Vice President of Chemistry at Tularik, Inc. Prior to that, Dr. Jaen held several positions in drug discovery and program management, from 1983 to 1996, at the Parke-Davis Pharmaceutical Research division of Warner-Lambert Company, a pharmaceutical company. Dr. Jaen also serves on the board of directors of R2M Pharma, Inc., PACT Pharma and the Bella Charitable Foundation. Dr. Jaen holds a B.S. in Chemistry from the Universidad Complutense de Madrid and a Ph.D. in Organic Chemistry from the University of Michigan. Jaen should serve as a director based on his position as one of our founders and as our President, his extensive experience in general management and business development and his experience in the field of biomedical research.
As the President, Co-Founder и Director of Arcus Biosciences Inc, the total compensation of Juan Jaen at Arcus Biosciences Inc is $2,126,900. There are 1 executives at Arcus Biosciences Inc getting paid more, with William Grossman having the highest compensation of $3,400,310.
Juan Jaen is 62, he's been the President, Co-Founder и Director of Arcus Biosciences Inc since 2015. There are 2 older and 13 younger executives at Arcus Biosciences Inc. The oldest executive at Arcus Biosciences Inc is Yasunori Kaneko, 66, who is the Lead Independent Director.
Juan's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.
Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead и Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Arcus Biosciences Inc executives and other stock owners filed with the SEC include: